Trial watch: Toll-like receptor ligands in cancer therapy
Accumulating evidence indicates that Toll-like receptor (TLR) agonists proficiently (re)instore cancer immunosurveillance as immunological adjuvants. So far, three TLR agonists have been approved by regulatory agencies for use in oncological applications. Additionally, these immunotherapeutics have...
Na minha lista:
| Principais autores: | , |
|---|---|
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
Taylor & Francis Group
2023-12-01
|
| coleção: | OncoImmunology |
| Assuntos: | |
| Acesso em linha: | https://www.tandfonline.com/doi/10.1080/2162402X.2023.2180237 |
| Tags: |
Sem tags, seja o primeiro a adicionar uma tag!
|